期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

拓扑替康治疗卵巢癌的研究

Advances in Topotecan research on OVC
暂未订购
导出
摘要 拓扑替康(Topotecan,TPT)是新一代的半合成、水溶性的喜树碱衍生物.它是一种细胞核内DNA拓扑异构酶Ⅰ特异性抑制剂,化学名称为9-二甲基氨基10-羟基盐酸喜树碱.自合成以来已有大量临床报道显示TPT对卵巢癌有较好的疗效.现将TPT在治疗卵巢癌中的研究进展作一综述. Topotecan（TPT） is a novel semi-synthetic, water-soluble analogue of camptothecin which is a specific inhibitor of DNA topoisomerase Ⅰ （Topo Ⅰ） . Its chemical name is 9- dimethyl, amido, 10-hydroxyl hydrochloric camptothecin. It is widely used around the world for clinical purposes, and lots of clinical reports have demonstrated that TPT achieves great therapeutic effects in the treatment of OVC. This paper summarizes the research progress of TPT in treating OVC.
作者 周建华 季宇彬
机构地区 哈尔滨商业大学生命科学与环境科学研究发展中心
出处 《哈尔滨商业大学学报（自然科学版）》 CAS 2007年第5期520-522,529,共4页 Journal of Harbin University of Commerce：Natural Sciences Edition
关键词 拓扑替康 卵巢癌 疗效 拓扑异构酶Ⅰ TPT ovarian cancer therapeutic effects Topoi
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献14

  • 1DENNIS M J,BEIJNEN J H.An Overview of the Clinical pharmacology of topotecan[J].Semin Oncol,1997,24(5):12-18.
  • 2ROWINSKY E K,GROCHOW L B,BENDRICKS C B,et al.Phase Ⅰ and pharmacologic study of topotecan:a novel topoismerase Ⅰ inhibitor[J].Clin Oncol,1992,10 (4):647 -656.
  • 3SCHELLENS J H,GREEMERS G J,BEIJNEN J H,et al.Bioavailahility and pharmacokinetics of oral topotecan:a new topois merase Ⅰ inhibitor[J].Br Cancer,1996,73(10):1268-1271.
  • 4SWISHER E M,MUTCH D G,RADER J S,et al.Topotecan in platinum-and paclitaxel-resistant ovarian cancer[J].Gynecol Oncd 1997,66(3):480 -486.
  • 5KUDELKA A P,TRESUKOSOL D,EDWARDS C L,et al.Phase Ⅱ study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian cancinoma[J].Clin Oncol,1996,14(5):1552-1557.
  • 6CREEMERS G J,BOLIS G,GORE M,et al.Scarfone G Topotecan,an active drug in the second-line treatment of epithelial ovarian cancer:results of a large European phase Ⅱ study[J].Clin Oncol,1996,14(12):3056 -3061.
  • 7GORDON A,BOOKMAN M,MALMSTROM H,et al.Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel:International Topotecan Study Group trial[J].Proc Am Soc Cline Oncol,1997,15(6):282 -283.
  • 8GORE M,CARMICHAEL J,GORDON A,et al.Topotecan versus paclitaxel for the treatment of reccurent epithelial ovarian cancer[J].Clin Oncol,1997,15(6):2183 -2193.
  • 9GWYTHER S,BOLIS G,GORE M,et al.Experience with independent radiological review during a topotecan trail in ovarian cancer[J].Ann Oncol,1997,8(5):463-468.
  • 10BOOKMAN M A,MALMSTORM L H,BOLSG,et al.Topotecon for the treatment of advanced epithelial ovarian cancer:an popenlabel phase Ⅱ study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel[J].Clin Oncol,1998,16(10):3345 -3352.

二级参考文献23

  • 1蔡树模,汤洁,范建玄,翁仲颖,章桂红.紫杉醇治疗难治性卵巢癌和输卵管癌的临床疗效（附30例分析）[J].中华肿瘤杂志,1995,17(2):135-138. 被引量：39
  • 2Bookman MA,McGuire WP Ⅲ ,Kilpatrick D,et al.Carboplatin and paclitaxel in ovarian carcinoma: a phase Ⅰ study of the Gynecologic Oncology Group [J].J Clin Oncol,1996,14:1895- 1902.
  • 3McGuire WP,Hoskins WJ,Brady MF,et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer [J].N Engl J Med,1996,334:1- 6.
  • 4Ten Bokkel Huinink W,Gore M,Carmichael J,et al.Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J].J Clin Oncol,1997,15:2183- 2193.
  • 5Eisenhauer EA,ten Bokkel Huinink WW,Swenerton KD,et al.European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion [J].J Clin Oncol,1994,12:2654- 2666.
  • 6Burris H,Kuhn J,Johnson R,et al.SKF 104864.Preclinical studies of a new topoisomerase Ⅰ inhibitor [J].Proc Am Assoc Cancer Res,1990,31:431(abstr).
  • 7Armstrong DK,Rowinsky EK,Donehower R,et al.A phase Ⅱ trial of topotecan as salvage therapy in epithelial ovarian cancer [J].Proc Am Soc Clin Oncol,1995,14:A769(abstr).
  • 8Bookman MA,Malmstrom H,Bolis G,et al.Topotecan for the treatment of advanced epithelial ovarian cancer: An open label phase Ⅱ study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel [J].J Clin Oncol,1998,16:3345- 3352.
  • 9McGuire WP,Blessing JA,Bookman MA,et al.Topotecan has substantial antitumor activity as first line salvage therapy in platinum sensitive epithelial ovarian carcinoma:A Gynecologic Oncology Group Study [J].J Clin Oncol,2000,18:1062- 1067.
  • 10Cannistra S.Is there a best choice of the second-line agent in the treatment of recurrent potentially platinum-sensitive ovarian cancer[J].J Clin Oncol,2002,20(5):1158～1160.

共引文献11

哈尔滨商业大学学报（自然科学版）
2007年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部